Corvus Pharmaceuticals (CRVS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Corvus Pharmaceuticals (CRVS) is Neutral.

The composite score behind that read is -0.08, weighing +0.13 of bullish evidence against -0.24 bearish.

Corvus Pharmaceuticals last closed at $10.52, +3.04% on the session.

Against the IVW growth benchmark the position is +2.24% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

6 graded predictions for CRVS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Corvus Pharmaceuticals in the 21st percentile on return on equity, where 100 is best.

Corvus Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $858.88M.

StockMap tracks Corvus Pharmaceuticals as the 140th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Corvus Pharmaceuticals ranks 193rd of 381 in the group, against a group median of -0.08.